Clinical trials: Unfractionated Heparin
Venous Thromboembolism, Antenatal Deep Vein Thrombosis
LMWH Compliance in Pregnancy
This is a prospective chart study that will aim to assess objective data on compliance levels to low molecular weight heparin (LMWH) injections among pregnant and postnatal women undergoing VTE thromboprophylaxis treatment at…
- Trial name
- NCT05066867
- Testing
- Smart sharps bin - collects data on compliance
- Where
- Ireland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Cork University Maternity Hospital
Venous Thromboembolism
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery
The primary objective was to compare the efficacy of once daily [q.d.] subcutaneous [s.c.] injections of Semuloparin sodium (AVE5026) with q.d. s.c.
- Trial name
- SAVE-HIP1 (NCT00697099)
- Testing
- Semuloparin sodium, Enoxaparin sodium
- Where
- 30 sites in United States, Argentina and 28 more
- Volunteers
- 2,326 people
- Sponsor
- Sanofi
Healthy
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following Heparin
Normal subjects will receive unfractionated heparin followed by a single dose of PER977 with dose escalation by cohort. Ten subjects enrolled in Cohort 4 will receive a single dose of PER977 followed by a one-week washout and…
- Trial name
- NCT02206087
- Testing
- PER977, Heparin Sodium
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Esophageal Neoplasms
Addition of Enoxaparin to Neoadjuvant Chemoradiation of Esophageal Cancer
This is a randomized, single blind, multi-center, phase two clinical trial. Inclusion criteria are consist of non-metastatic esophageal cancer who are going to receive chemo-radiotherapy.
- Trial name
- NCT03254511
- Testing
- Enoxaparin Sodium 40 MG/0.2 ML Subcutaneous Injectable, Radiotherapy, Chemotherapeutic Combinations
- Where
- Iran
- Volunteers
- 100 people
- Sponsor
- Mashhad University of Medical Sciences
Extracorporeal Membrane Oxygenation Complication
Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation
The purpose of this study was to evaluate the efficacy and safety of bivalirudin in anticoagulation therapy in patients with extracorporeal membrane oxygenation (ECMO) compared with unfractionated heparin.
- Trial name
- NCT06275555
- Testing
- bivalirudin, unfractionated heparin
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Xiaotong Hou
Recurrent Abortion
Low-molecular-weight Heparin (LMWH) Versus Unfractionated Heparin (UFH) in Pregnant Women With Recurrent Abortion Secondary to Antiphospholipid Syndrome
The aim of this study is to compare the efficacy and safety of Low molecular weight heparin (LMWH) plus low dose aspirin (LDA) with unfractionated heparin(UFH) plus LDA in women with recurrent pregnancy loss associated with…
- Trial name
- NCT01051778
- Testing
- enoxaparin 40mg plus low dose aspirin, Heparin calcium5,000 U twice daily plus low dose aspirin
- Where
- 2 sites in Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
Coronary Artery Disease
Feasibility and Safety Study Comparing REG1 Anticoagulation System With Unfractionated Heparin in Elective PCI
The purpose of this study is to determine if it is feasible and safe to use the REG1 Anticoagulation System instead of unfractionated heparin during percutaneous coronary intervention (PCI) in subjects with coronary artery…
- Trial name
- REVERSAL-PCI (NCT00715455)
- Testing
- REG1, Unfractionated Heparin
- Where
- 6 sites in United States, Argentina
- Volunteers
- 26 people
- Sponsor
- Regado Biosciences, Inc.
Venous Thromboembolism, Brain Tumors
Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients
In patients with malignant glioma, to determine the efficacy of prophylaxis with LMWH (dalteparin) compared to placebo, both commenced beyond the immediate postoperative period, for the prevention of VTE.
- Trial name
- NCT00135876
- Testing
- dalteparin
- Where
- 14 sites in United States, Australia and 2 more
- Volunteers
- 512 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Pain, Bruising
Comparing Pain and Bruising of Subcutaneous Heparin Injection
Subcutaneous heparin injection is one of the most frequent nurses' clinical care. This study aimed to Identify and compare the effects of four different injection duration on pain and bruising associated with subcutaneous…
- Trial name
- NCT01645774
- Testing
- 10s injections duration, 10s injection duration and waiting 10s before withdrawing the needle, 15s injection duration and waiting 5s before withdrawing the needle
- Volunteers
- 90 people
- Sponsor
- Mashhad University of Medical Sciences
Sarcoma, Soft Tissue Sarcoma
LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology
Aspirin and low molecular weight heparin (LMWH) are both commonly employed pharmacologic methods of venous thromboembolism (VTE) prophylaxis after orthopaedic surgery.
- Conditions
- Sarcoma, Soft Tissue Sarcoma, Bone Sarcoma, Bone Metastases
- Trial name
- NCT03244020
- Testing
- Aspirin 325mg, Enoxaparin 40Mg/0.4mL Prefilled Syringe
- Where
- 10 sites in United States
- Volunteers
- 2,868 people
- Sponsor
- Massachusetts General Hospital
Sodium, Renal Function
The Effect of Sodium on Erythrocyte Salt Sensitivity, Syndecan-1 and Heparin Sulfate in Healthy Subjects.
The study was a double-blinded, randomized, placebo-controlled cross-over study. 27 healthy subjects received a four days standardized, sodium reduced diet (100 mmol sodium) and treatment with sodium chloride (200 mmol sodium) or…
- Conditions
- Sodium, Renal Function, Blood Pressure
- Trial name
- EGNA (NCT06968182)
- Testing
- Sodium Chloride
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Frank Mose
The Primary Study Objective is to Assess the Efficacy and, Safety of Extended 4-week Heparin Prophylaxis Compared to
ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER.
Overall, only limited evidence exists regarding the clinical benefit of antithrombotic prophylaxis after laparoscopic surgery for cancer.
- Conditions
- The Primary Study Objective is to Assess the Efficacy and, Safety of Extended 4-week Heparin Prophylaxis Compared to, Prophylaxis Given for 8±2 Days After Planned Laparoscopic, Surgery for Colorectal Cancer.
- Trial name
- PRO-LAPS I (NCT01589146)
- Testing
- Heparin, Low-Molecular-Weight
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- University Of Perugia
Catheter-Related Infections
Heparin Versus Saline in Peripheral Venous Catheter
A clinical, prospective. controlled and randomized study with patients with a peripheral venous catheter. Patients will be randomized to either receive heparin or saline.
- Trial name
- NCT02970409
- Testing
- saline, Heparin
- Where
- Spain
- Volunteers
- 354 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
Percutaneous Coronary Intervention
Comparison of Anticoagulation for All-comers Undergoing Percutaneous Coronary Revascularization Trial
The purpose of this trial is to determine whether bivalirudin is non-inferior to unfractionated heparin in patients with stable angina, unstable angina, or non-ST segment elevation myocardial infarction undergoing percutaneous…
- Trial name
- CALIFORNIA (NCT02448550)
- Testing
- Bivalirudin, Unfractionated heparin
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Kaiser Permanente
Bruises
Patients Preference With Self-Injection: The PRISM Study
The purpose of this study is to determine which short-acting blood thinner (low-molecular-weight heparin [Enoxaparin] or unfractionated heparin) is associated with less discomfort and bruising when given as a subcutaneous (under…
- Trial name
- NCT00253396
- Testing
- Unfractionated heparin, Enoxaparin
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Hamilton Health Sciences Corporation
Lung Edema
Heparin-binding Protein and Lungedema in ICU Patients.
The goal of this single center observational cohort study is to investigate the relationship between physiological measures of lung oedema, and the biomarker Heparin-binding Protein (HBP).
- Trial name
- NCT07434908
- Where
- Sweden
- Volunteers
- 25 people
- Sponsor
- Umeå University
Recurrent Urinary Tract Infections
Recurrent Urinary Tract Infections and Heparin (RUTIH Trial)
Urinary Tract Infections (UTIs) are the second most common infection in the body. UTIs account for five percent of all visits to primary care physicians.
- Trial name
- NCT02246270
- Testing
- Intravesical Heparin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Oklahoma
Coronary Disease, Angina Pectoris
Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3)
The purpose of this study is to determine whether bivalirudin given during PCI is associated with better outcomes compared to un-fractionated heparin.
- Trial name
- NCT00262054
- Testing
- Bivalirudin, Un-fractionated heparin
- Where
- 4 sites in Germany
- Volunteers
- 4,570 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Venous Thromboembolism, Deep Vein Thrombosis (DVT)
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the legs and/or blood clots in the lungs.
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Thromboembolism
- Trial name
- NCT00986154
- Testing
- edoxaban tosylate(DU-176b), low molecular weight heparin/unfractionated heparin, warfarin
- Where
- 454 sites in United States, Argentina and 36 more
- Volunteers
- 8,292 people
- Sponsor
- Daiichi Sankyo
Deep Vein Thrombosis, Pulmonary Embolism
Evaluation of Anti-Xa Levels in Surgery Patients Receiving Weight-based Heparin
The purpose of this study is to determine if weight-based heparin infusions at a rate of 10 units/kg/hour are sufficient to maintain a target anti-Xa of 0.1-0.35 IU/mL for VTE prophylaxis in patients undergoing microvascular…
- Conditions
- Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism
- Trial name
- NCT03516656
- Testing
- Standard heparin dose, Real time heparin dose adjustment
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Utah